3 results
To analyze the molecular effects and dose-response relationship of HBOT in patients with moderate-to-severe UC refractory to medical therapy, more specifically to evaluate: - Clinical, endoscopic, histological and ultrasonographic disease activity-…
In this study we will investigate how quickly and to what extent ralmitaront is absorbed, transported, and eliminated from the body (this is called pharmacokinetics). Ralmitaront is radioactively labelled with carbon 14 (14C). In this way…
The primary objective of this trial is to test if these favorable results with the DLBP can be upheld in a multicenter randomized controlled trial with patients up to 65 years with a displaced FNF. We hypothesize that the DLBP is superior compared…